Orgenesis Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Orgenesis recent Real Value cannot be determined due to lack of data. The prevailing price of Orgenesis is $0.0. Our model determines the value of Orgenesis from analyzing the company fundamentals such as Return On Equity of -7.27, shares owned by insiders of 21.16 %, and Current Valuation of 23.01 M as well as examining its technical indicators and probability of bankruptcy. . In general, most investors support acquiring undervalued entities and selling overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Orgenesis Total Value Analysis
Orgenesis is now forecasted to have valuation of 23.01 M with market capitalization of 10.07 M, debt of 22.62 M, and cash on hands of 2.3 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Orgenesis fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.01 M | 10.07 M | 22.62 M | 2.3 M |
Orgenesis Investor Information
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.26. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Orgenesis recorded a loss per share of 8.0. The entity last dividend was issued on the 16th of November 2017. The firm had 1:10 split on the 25th of September 2024. Based on the key indicators related to Orgenesis' liquidity, profitability, solvency, and operating efficiency, Orgenesis is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Orgenesis Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Orgenesis has an asset utilization ratio of 3.64 percent. This implies that the OTC Stock is making $0.0364 for each dollar of assets. An increasing asset utilization means that Orgenesis is more efficient with each dollar of assets it utilizes for everyday operations.Orgenesis Ownership Allocation
The market capitalization of Orgenesis is $10.07 Million. Orgenesis has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Orgenesis Profitability Analysis
The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M.Orgenesis Growth Indicators
Investing in growth stocks can be very risky. If the company such as Orgenesis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |